Weiting Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6976197/publications.pdf

Version: 2024-02-01

		1684188	1588992	
8	129	5	8	
papers	citations	h-index	g-index	
9	9	9	147	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells. Journal of Hazardous Materials, 2018, 355, 1-9.	12.4	53
2	Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncology, 2019, 94, 80-85.	1.5	21
3	Use of a Remote Oncology Pharmacy Service Platform for Patients With Cancer During the COVID-19 Pandemic: Implementation and User Acceptance Evaluation. Journal of Medical Internet Research, 2021, 23, e24619.	4.3	18
4	A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. Frontiers in Pharmacology, 2020, 11, 619.	3.5	16
5	Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients. Annals of Translational Medicine, 2020, 8, 236-236.	1.7	7
6	Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	6
7	Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUCâ€guided dosing in nonsmall cell lung cancer. Clinical and Translational Medicine, 2021, 11, e354.	4.0	5
8	Clinical pharmacist participation in selecting and dosing targeted drugs for a patient with ALK-positive non-small cell lung cancer: a case report. Annals of Translational Medicine, 2021, 9, 1488-1488.	1.7	3